the aid library

LIST OPTIONS

Filter

8462

Sort by:

Direction:

Download (95)

View PDF (118)

Statement to African Union Member States on the deployment of the AstraZeneca COVID-19 Vaccine to the continent and concerns about adverse event reports coming from Europe

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2021) CC

19 March 2021

Download (550)

View PDF (1033)

Efforts to Build Infection Control Capacity in in Liberia, Guinea, and Sierra Leone During the Ongoing Ebola Outbreak

Benjamin J. Park, MD; Centers for Disease Control and Prevention (CDC); Department of Health and Human Services - USA (2015) C_CDC

Download (133)

View PDF (168)

Instruments internationaux sur l’utilisation des antimicrobiens dans les secteurs de la santé humaine, des animaux et des plantes

the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO) (2020) C_WHO

La publication fournit une vue d'ensemble et une analyse des instruments internationaux qui établissent des normes relatives à l'utilisation des antimicrobiens dans les secteurs humain, animal et végétal, et à leur rejet dans l'environnement. L'objectif de ce document est d'identifier les instr... more

Download (152)

View PDF (178)

International instruments on the use of antimicrobials across the human, animal and plant sectors

the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO) (2020) C_WHO

The publication provides an overview and analysis of international instruments that set standards related to the use of antimicrobials across the human, animal and plant sectors, and their release into the environment. The purpose of the document is to identify existing instruments and standards in ... more

Download (202)

View PDF (204)

Situational Analysis of Antimicrobial Use and Resistance in Humans and Animals in Zimbabwe

The Center for Disease Dynamics, Economics & Policy CDDEP (2017) C2

This situation analysis has gathered information about the current state of AMR, contributing factors and antimicrobial use in Zimbabwe from the human, animal, agricultural and environmental sectors. Data has been gathered from different sectors such as the general public, academia, the Ministry of ... more

Download (156)

View PDF (125)

Rapport global de suivi de la mise en oeuvre des actions de lutte contre l'exploitation sexuelle des enfants à des fins commerciales - Burkina Faso

ECPAT France et ECPAT Luxembourg (2016) C2

L’Agenda pour l’action contre l’exploitation sexuelle des enfants à des fins commerciales fournit un cadre détaillé et établit des catégories d’actions devant être prises par les gouvernements en partenariat avec les organisations de la société civile et les autres acteurs-clés pou... more

Download (108)

View PDF (163)

An integrated, Sustainable Framework to Elimination of Communicable Diseases in the Americas. Concept Note

Pan American Health Organisation (PAHO) (2019) C_WHO

The objective of this concept note and the framework it outlines is the elimination of a group of CDs and the negative health effects they generate, which together create a tangible burden on affected individuals, their families and communities, and on health care systems throughout the Region. Thou... more

Download (42)

View PDF (41)

Childhood respiratory disease linked to the enviroment

World Health Organization WHO (2009) CC2

Childhood Respiratory Diseases & the Environment learning objectives •To understand how the respiratory tract is affected by the environment •To describe respiratory diseases linked to the environment •To list one population-level intervention and one personal-level intervention for d... more

Download (274)

View PDF (370)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (2207)

View PDF (2482)

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer)
recommended

World Health Organization WHO WHO (2012) C_WHO

Guidance for health workers

Download (160)

View PDF (252)

A World at Risk

Global Preparedness Monitoring Board (2019) C_WHO

Annual report on global preparednessfor health emergencies The next pandemic is not a question of if, but when—and the world is woefully unprepared, according to the first annual report from the Global Preparedness Monitoring Board. The WHO and the World Bank convened the independent group after ... more

Download (122)

View PDF (108)

Results Report - Programme budget 2020–2021 - Executive Summary

World Health Organization (WHO) World Health Organization (WHO) (2022) CC

This results report for the biennium 2020–2021 presents the progress towards the triple billion targets, outcomes and outputs, based on the GPW 13 results framework and indicators. It uses structured methodologies, both quantitative and qualitative, for measuring and analysing the achievements and... more

Download (797)

View PDF (1192)

WASH’Nutrition: A practical guidebook on increasing nutritional impact through integration of WASH and Nutrition programmes

J. Dodos Action Contre la Faim (ACF) International, (2017) C1

For practitioners in humanitarian and development contexts

Download (96)

View PDF (109)

Draft Proposed programme budget 2022–2023: Building forward better

World Health Organization (WHO) World Health Organization (WHO) (2021) CC

The development of this draft Proposed programme budget 2022–2023 comes at a unique moment for WHO. The world is in the grip of the coronavirus disease (COVID-19) pandemic and faces health, social and economic consequences on an unprecedented scale. Although it is not known when the COVID-19 pande... more

Download (232)

View PDF (229)

Situational Analysis Report on Antimicrobial Resistance in Pakistan

The Center for Disease Dynamics, Economics & Policy CDDEP (2016) C2

Pakistan Global Antibiotic Resistance Partnership (GARP) was formed in the wake of international and national efforts for AMR curtailment. A group of experts from microbiology, infectious diseases and veterinary medicine formed a core group at the organizational meet... more

Download (505)

View PDF (1195)

Nigeria: National Family Planning Communication Plan (2017-2020)

Family Planning Services - Federal Ministry of Health (2017) C2

Strategy for Increasing the use of Modern Contraceptives in Nigeria

Download (99)

View PDF (171)

Burkina Faso: Malaria Operational Plan FY 2019

U.S. Global Malaria Coordinator (2019) C2

This FY 2019 Malaria Operational Plan presents a detailed implementation plan for Burkina Faso, based on the strategies of PMI and the National Malaria Control Program (NMCP). It was developed in consultation with the NMCP and with the participation of national and international partners involved in... more

Download (235)

View PDF (536)

Moscow declaration to end TB (Russian edition)

World Health Organization (2017) C_WHO

First WHO Global Ministerial Conference Ending TB in the Sustainable Development Era: A Multisectoral Response Moscow, Russian Federation, 16-17 November 2017 Первая глобальная министерская конференция ВОЗ Ликвидировать туберкуле�... more

Download (25)

View PDF (66)

Hearts - D: Diagnosis and Management of Type 2 Diabetes 2020

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabe... more

Download (180)

View PDF (260)

World Report on Vision

World Health Organization WHO (2019) C_WHO

At present at least 2.2 billion people around the world have a vision impairment, of whom at least 1 billion have a vision impairment that could have been prevented or is yet to be addressed. The world faces considerable challenges in terms of eye care, including inequalities in the coverage and qua... more

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer) recommended

Treatment of Mycobacterium Ulcerans Disease (Buruli Ulcer)
recommended